Evidence map›Paper›PMID 18706282›Full record

ReviewCurrent atherosclerosis reports2008

HDL therapy for cardiovascular diseases: the road to HDL mimetics.

C Roger White, Geeta Datta, Zhenghao Zhang, Himanshu Gupta, David W Garber, Vinod K Mishra, Mayakonda N Palgunachari, Shaila P Handattu, Manjula Chaddha, G M Anantharamaiah

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current atherosclerosis reports, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

C Roger WhiteVascular Biology and Hypertension Program, University of Alabama, Birmingham, 1046 Zeigler Research Building, 703 South 19th Street, Birmingham, AL 35294, USA. crwhite@uab.edu
Geeta Datta
Zhenghao Zhang
Himanshu Gupta
David W Garber
Vinod K Mishra
Mayakonda N Palgunachari
Shaila P Handattu
Manjula Chaddha
G M Anantharamaiah
University of Alabama at Birmingham · US

Funding

SYNTHETIC PEPTIDE STUDIES OF THE AMPHIPATHIC HELIXP01HL034343 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SEGREST, JERE P · 1985 to 2012
$18.8M
HDL and Vascular Injury in Type 2 DiabetesR01DK070040 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI WHITE, C ROGER · 2005 to 2008
$1.2M
Modulators of HDL structure-functionR01HL089328 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ANANTHARAMAIAH, G M · 2007 to 2007
$363k
NHLBI NIH HHS P01 HL034343NHLBI NIH HHS R01 HL089328NIDDK NIH HHS R01 DK070040
6 · The paper itself

Abstract

3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) are currently the drug of choice for the clinical management of elevated low-density lipoprotein (LDL) cholesterol. Although statin treatment provides an overall improvement in outcomes, clinical trial data reveal a significant number of cardiac events despite reaching targeted LDL levels. A low serum high-density lipoprotein (HDL) cholesterol level is an independent predictor of cardiovascular risk. Accordingly, there has been interest in determining whether HDL elevation, in addition to LDL lowering, further reduces risk in patients with coronary artery disease. Several commonly prescribed lipid-lowering therapies modestly raise HDL, but their use may be limited by the development of adverse reactions. Emerging data suggest that HDL quality and function may also be significantly reduced by atherosclerosis and other inflammatory diseases. The goal of this review is to discuss the current status of HDL therapeutics, with emphasis on a novel class of agent, the apolipoprotein A-I mimetic peptides, which improve the functional properties of HDL cholesterol.

Indexed as

AnimalsApolipoprotein A-IAtherosclerosisCardiovascular DiseasesCholesterol Ester Transfer ProteinsCholesterol, HDLClofibric AcidHumansHydroxymethylglutaryl-CoA Reductase InhibitorsLipoproteinsLiverPeptide FragmentsAc-hE18A-NH(2)Apolipoprotein A-ICholesterol Ester Transfer ProteinsCholesterol, HDLClofibric AcidD-4F peptideHydroxymethylglutaryl-CoA Reductase InhibitorsLipoproteinsPeptide Fragments

Identifiers

PMID18706282
OpenAlexW2038484394

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.